Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity
{{output}}
We aimed to evaluate the long-term tamoxifen benefit by progesterone receptor (PR) levels in postmenopausal lymph node-negative breast cancer patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2-negative (HER2) tumors in the S... ...
